

Contents

Introduction	xi
About the Author	xiii
1. Background	1
1.1 Introduction	1
1.2 Definition and History of Traditional Clinical Trials	2
1.3 Definition of Adaptive Clinical Trial.....	5
1.4 Precursors to Modern Adaptive Clinical Trials.....	10
1.5 New Enabling Technologies and Other Requirements for Adaptive Trials	13
1.6 Rationale for Adaptive Clinical Trials	14
1.7 Learn and Confirm	16
1.8 Classification and Terminology of Adaptive Clinical Studies	20
1.9 Non-Adaptive Study Designs.....	21
1.10 Limitations of Adaptive Clinical Trials	21
1.11 Performance Criteria for Well-Designed Clinical Trials	22
1.12 Evolving Regulatory Environment for Adaptive Clinical Trials.....	27
1.13 Regulatory Guidance from the FDA	30
References	36
2. Conventional Statistics.....	37
2.1 Basic Statistics.....	37
2.2 Statistical Schools.....	37
2.3 Frequentist Method	38
2.4 Bayesian Method.....	40
2.5 Likelihood Method.....	40
2.6 Other Schools.....	41
2.7 Descriptive Statistics.....	41
2.8 Inferential Statistics	41
2.9 Comparative Statistics	43
2.10 Hypothesis Testing	44
2.11 Null Hypothesis and Standard of Proof in Clinical Trials	44
2.12 Example of Inference and Hypothesis Testing	45
2.13 Statistical Tests and Choice of Statistical Test.....	47
2.14 Examples of Statistical Tests.....	48
2.15 Fundamental Statistical Assumptions.....	50
2.15.1 Background.....	50
2.15.2 Parametric Assumption.....	52

2.15.3	Continuity and Linearity Assumptions	53
2.15.4	Constant Hazard Ratio Assumptions.....	53
2.15.5	Independent and Random Sampling.....	53
2.15.6	Independence of Events	54
3.	Statistics Used in Adaptive Clinical Trials	55
3.1	Introduction	55
3.2	Preserving the Alpha.....	55
3.3	What Is Alpha?	56
3.4	Misconception about p Values	58
3.5	Splitting the Alpha.....	59
3.6	Methodologies for Allocating Alpha	60
3.6.1	Bonferroni Correction	60
3.6.2	Holm Correction	61
3.6.3	Other Methods	61
3.7	Evolution of Adaptive Analytic Methods: Interim Analysis.....	62
3.8	Adaptive Methods	65
3.9	Limitations of Adaptive Statistical Techniques.....	69
3.10	Bayesian Approach	71
3.11	Simulations and Modeling	72
3.12	The FDA's Stance on Adaptive Techniques	73
	References	93
4.	Specific Requirements for Adaptive Trials	95
4.1	Requirements for Endpoints in Adaptive Studies	95
4.2	Surrogates and Biomarkers	97
4.3	Practical Requirements	99
5.	Adaptive Randomization and Allocation.....	101
5.1	Traditional Fixed Allocation.....	101
5.2	Simple Randomization.....	102
5.3	Restricted and Blocked Randomization	102
5.4	Stratified, Nested, and Similar Randomization.....	103
5.5	Balancing (Covariate) Adaptive Randomization.....	104
5.6	Response (Outcome) Adaptive Randomization	105
5.7	Combination and Multimodal Randomization.....	106
5.8	Bayesian Randomization	107
5.9	Adaptation of Inclusion and Exclusion Criteria Based on Blinded Data	107
5.10	Patient Enrichment Adaptations.....	108
6.	Sample Size Reestimation	111
6.1	Background.....	111
6.2	Sample Size Reestimation Based on Blinded Data.....	112

6.3	Sample Size Reestimation Based on Unblinded Data	113
6.4	Adjustment in Follow-Up Time	114
6.5	Internal Pilot Studies	114
6.6	Additional Rules	115
	References	115
7.	Traditional Dosing	117
7.1	Introduction	117
7.2	Definitions and Objectives of Dose Selection	118
7.3	Issues.....	119
7.4	Pharmacokinetics.....	120
7.5	Factors Affecting Pharmacokinetics	122
7.6	Dose-Response Curves.....	122
7.7	Types of Dosing.....	123
7.7.1	Flat Doses.....	123
7.7.2	Dosing Based on a Baseline Characteristic.....	124
7.7.3	Titrated Dosing.....	124
7.8	Traditional Dose-Escalation and Dose-Ranging Studies	124
8.	Adaptive Dosing.....	129
8.1	Adaptive Dose Finding	129
8.2	Phase I Studies.....	131
8.3	3 + 3 and Related Designs.....	132
8.4	Continual Reassessment Method	134
8.5	Dose Escalation with Overdose Control.....	137
8.6	Stochastic Approximation Methods.....	138
8.7	Summary of Single-Parameter Models.....	138
8.8	Additional Models and Methods.....	139
8.9	Dose Adaptation in a Pivotal Study	140
8.10	Changes in Concomitant Medications and Procedures	141
	References	141
9.	Interim Analysis and Adaptive Termination of Study and Study Arms	143
9.1	Overview	143
9.2	Data and Safety Monitoring Boards.....	143
9.3	Stopping Rules.....	145
9.4	Individual Sequential Designs.....	145
9.5	Group Sequential Designs	146
	References	147
10.	Adaptive Changes in Study Design and Decision Rules.....	149
10.1	Overview	149
10.2	Changes to Follow-Up Period	149

10.3	Flexible Designs	149
10.4	Changing the Endpoints and Hypothesis.....	150
10.4.1	Changes Based on Blinded Data	150
10.4.2	Changes Based on Unblinded Data	150
10.5	Changes to Test Statistic or Analysis	151
10.5.1	Changes Based on Blinded Data	151
10.5.2	Changes Based on Unblinded Data	151
	References	152
11.	Seamless Designs and Adaptive Clinical Trial Conduct	155
11.1	Seamless Designs.....	155
11.2	Challenges in Adaptive Trials.....	156
11.3	Maintaining the Blind	156
11.4	Infrastructure and Operations.....	157
11.5	Adaptive Trial Protocols	159
12.	Analysis and Interpretation of Results.....	163
12.1	General Issues in Interpretation of Clinical Trial Results.....	163
12.2	Interpretation of Adaptive Trial Results.....	169
12.3	Documentation of Trial Integrity.....	170
12.4	Statistics of Adaptive Trial Analysis	171
12.5	Summary.....	172
	References	172
	Index.....	173